Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL).

被引：7

作者：

Khouri, Issa F. ^{[1
]}

Saliba, Rima M. ^{[1
]}

Hosing, Chitra ^{[1
]}

Valverde, Rosamar ^{[1
]}

Erwin, William D. ^{[1
]}

Fayad, Luis ^{[1
]}

Maadani, Farzaneh ^{[1
]}

Korbling, Martin J. ^{[1
]}

Okoroji, Grace-Julia ^{[1
]}

Stachowiak, Anne M. ^{[1
]}

Samuels, Barry I. ^{[1
]}

Anderlini, Paolo ^{[1
]}

Couriel, Daniel R. ^{[1
]}

de Lima, Marcos ^{[1
]}

Giralt, Sergio ^{[1
]}

Popat, Uday ^{[1
]}

Kebriaei, Partow ^{[1
]}

Ueno, Naoto T. ^{[1
]}

Qazilbash, Muzaffar H. ^{[1
]}

McLaughlin, Peter W. ^{[1
]}

Hagemeister, Fredrick B. ^{[1
]}

Younes, Anas ^{[1
]}

Podoloff, Donald A. ^{[1
]}

Champlin, Richard E. ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2006年 / 108卷 / 11期

关键词：

D O I：

10.1182/blood.V108.11.315.315

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

315

引用

页码：98A / 98A

页数：1

共 50 条

[1] Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in the treatment of non-Hodgkin's lymphoma (NHL):: Incorporation into autologous stem cell transplantation (ASCT) regimens
Nademanee, A
Krishnan, A
Fung, H
Raubitschek, A
Forman, S
Molina, A
ANNALS OF ONCOLOGY, 2005, 16 : 100 - 100
[2] Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
Gisselbrecht, C.
Bethge, W.
Duarte, R. F.
Gianni, A. M.
Glass, B.
Haioun, C.
Martinelli, G.
Nagler, A.
Pettengell, R.
Sureda, A.
Tilly, H.
Wilson, K.
BONE MARROW TRANSPLANTATION, 2007, 40 (11) : 1007 - 1017
[3] Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
C Gisselbrecht
W Bethge
R F Duarte
A M Gianni
B Glass
C Haioun
G Martinelli
A Nagler
R Pettengell
A Sureda
H Tilly
K Wilson
Bone Marrow Transplantation, 2007, 40 : 1007 - 1017
[4] Localization of yttrium 90 ibritumomab tiuxetan (90Y IT) in patients with CD20+ non-Hodgkin's lymphoma (NHL).
Jacobs, SA
Swerdlow, SA
Avril, N
Vidnovic, N
Foon, KA
Harrison, AM
McCarty, KS
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 177S - 177S
[5] Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma
Witzig, TE
SEMINARS IN ONCOLOGY, 2003, 30 (06) : 11 - 16
[6] Evaluation of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in patients with non-Hodgkin's lymphoma (NHL) having previously received autologous stem cell transplant (ASCT)
Jacobs, SA
McCook, B
Torok, F
Avril, N
Vidnovic, N
Joyce, J
Molina, A
BLOOD, 2004, 104 (11) : 395B - 395B
[7] Safety and efficacy of retreating follicular non-Hodgkin's lymphoma with 90Y ibritumomab tiuxetan (zevalin).
Shah, J.
Mueh, I.
Lister, J.
Jasthy, S.
Gregory, M.
Mckay, C.
Krumdieck, R.
Forero, A.
JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (01) : S303 - S303
[8] Dose finding trial of yttrium 90 (90Y) ibriturnomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
Flinn, IW
Kahl, BS
Frey, E
Bianco, JA
Hammes, RJI
Billing, LS
Swinnen, LJ
Sgouros, G
Wahl, RL
BLOOD, 2004, 104 (11) : 256A - 256A
[9] Experience with yttrium 90 ibritumomab tiuxetan after autologous stem cell transplant (ASCT) in patients with non-Hodgkin's lymphoma (NHL).
Joyce, J
Schuster, MW
McCook, B
Torok, F
Avril, N
Vidnovic, N
Jacobs, SA
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 602S - 602S
[10] Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)
Swinnen, L. J.
Flinn, I. W.
Kahl, B. S.
Frey, E.
Rogers, K.
Jung, M.
Jacene, H.
Wahl, R. L.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →